Vijay Kumar
Stock Analyst at Evercore ISI
(2.81)
# 2,681
Out of 4,371 analysts
512
Total ratings
45.5%
Success rate
1.3%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintained: Buy | $106 | $81.93 | +29.38% | 21 | Jun 4, 2026 | |
| GH Guardant Health | Upgraded: Buy | $95 → $160 | $133.06 | +20.25% | 5 | Jun 2, 2026 | |
| CAI Caris Life Sciences | Maintained: Buy | $30 | $17.28 | +73.61% | 8 | May 9, 2026 | |
| ENOV Enovis | Maintained: Buy | $35 → $36 | $22.86 | +57.48% | 13 | May 8, 2026 | |
| PEN Penumbra | Maintained: Buy | $345 → $335 | $320.63 | +4.48% | 7 | May 7, 2026 | |
| EW Edwards Lifesciences | Maintained: Buy | $93 | $87.45 | +6.35% | 32 | May 5, 2026 | |
| WAT Waters | Maintained: Buy | $350 | $376.47 | -7.03% | 14 | May 5, 2026 | |
| BDX Becton, Dickinson and Company | Initiated Coverage: Buy | $275 → $180 | $149.56 | +20.35% | 16 | May 4, 2026 | |
| ILMN Illumina | Maintained: Buy | $150 → $155 | $168.06 | -7.77% | 22 | May 1, 2026 | |
| SYK Stryker | Maintained: Buy | $365 → $355 | $301.21 | +17.86% | 26 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $20 | $17.99 | +11.17% | 21 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 → $160 | $107.51 | +48.82% | 4 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8.5 → $8 | $9.52 | -15.97% | 17 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 → $16 | $15.35 | +4.23% | 11 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $85 → $80 | $63.81 | +25.37% | 13 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $317.32 | - | 3 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $225 | $186.64 | +20.55% | 16 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $480 | $418.82 | +14.61% | 43 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $134 → $120 | $90.78 | +32.19% | 24 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $160 → $140 | $138.37 | +1.18% | 17 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $22 | $19.35 | +13.70% | 19 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $96 → $80 | $48.85 | +63.77% | 26 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $35 | $22.84 | +53.24% | 17 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $1,400 → $1,425 | $1,180.48 | +20.71% | 16 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $118 → $108 | $102.40 | +5.47% | 19 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $650 → $575 | $482.03 | +19.29% | 21 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $52 → $56 | $73.93 | -24.25% | 10 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $104 → $120 | $86.69 | +38.42% | 23 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $4.17 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 → $150 | $109.13 | n/a | 14 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 → $2.5 | $1.50 | n/a | 4 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $93 | $264.59 | n/a | 1 | Nov 9, 2022 |
Medtronic
Jun 4, 2026
Maintained: Buy
Price Target: $106
Current: $81.93
Upside: +29.38%
Guardant Health
Jun 2, 2026
Upgraded: Buy
Price Target: $95 → $160
Current: $133.06
Upside: +20.25%
Caris Life Sciences
May 9, 2026
Maintained: Buy
Price Target: $30
Current: $17.28
Upside: +73.61%
Enovis
May 8, 2026
Maintained: Buy
Price Target: $35 → $36
Current: $22.86
Upside: +57.48%
Penumbra
May 7, 2026
Maintained: Buy
Price Target: $345 → $335
Current: $320.63
Upside: +4.48%
Edwards Lifesciences
May 5, 2026
Maintained: Buy
Price Target: $93
Current: $87.45
Upside: +6.35%
Waters
May 5, 2026
Maintained: Buy
Price Target: $350
Current: $376.47
Upside: -7.03%
Becton, Dickinson and Company
May 4, 2026
Initiated Coverage: Buy
Price Target: $275 → $180
Current: $149.56
Upside: +20.35%
Illumina
May 1, 2026
Maintained: Buy
Price Target: $150 → $155
Current: $168.06
Upside: -7.77%
Stryker
May 1, 2026
Maintained: Buy
Price Target: $365 → $355
Current: $301.21
Upside: +17.86%
May 1, 2026
Maintained: Buy
Price Target: $16 → $20
Current: $17.99
Upside: +11.17%
May 1, 2026
Maintained: Buy
Price Target: $170 → $160
Current: $107.51
Upside: +48.82%
Apr 30, 2026
Maintained: Hold
Price Target: $8.5 → $8
Current: $9.52
Upside: -15.97%
Apr 30, 2026
Maintained: Hold
Price Target: $17 → $16
Current: $15.35
Upside: +4.23%
Apr 30, 2026
Maintained: Buy
Price Target: $85 → $80
Current: $63.81
Upside: +25.37%
Apr 23, 2026
Maintained: Buy
Price Target: n/a
Current: $317.32
Upside: -
Apr 21, 2026
Maintained: Buy
Price Target: $225
Current: $186.64
Upside: +20.55%
Apr 20, 2026
Maintained: Hold
Price Target: $480
Current: $418.82
Upside: +14.61%
Apr 16, 2026
Maintained: Buy
Price Target: $134 → $120
Current: $90.78
Upside: +32.19%
Apr 6, 2026
Rated: Buy
Price Target: $160 → $140
Current: $138.37
Upside: +1.18%
Apr 6, 2026
Rated: Buy
Price Target: $23 → $22
Current: $19.35
Upside: +13.70%
Apr 6, 2026
Rated: Buy
Price Target: $96 → $80
Current: $48.85
Upside: +63.77%
Apr 6, 2026
Rated: Buy
Price Target: $45 → $35
Current: $22.84
Upside: +53.24%
Apr 6, 2026
Rated: Buy
Price Target: $1,400 → $1,425
Current: $1,180.48
Upside: +20.71%
Apr 6, 2026
Rated: Buy
Price Target: $118 → $108
Current: $102.40
Upside: +5.47%
Apr 6, 2026
Maintained: Buy
Price Target: $650 → $575
Current: $482.03
Upside: +19.29%
Apr 6, 2026
Rated: Buy
Price Target: $52 → $56
Current: $73.93
Upside: -24.25%
Jan 5, 2026
Upgraded: Buy
Price Target: $104 → $120
Current: $86.69
Upside: +38.42%
May 19, 2025
Maintained: Hold
Price Target: $3
Current: $4.17
Upside: n/a
Nov 12, 2024
Maintained: Buy
Price Target: $160 → $150
Current: $109.13
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $2 → $2.5
Current: $1.50
Upside: n/a
Nov 9, 2022
Maintained: Buy
Price Target: $93
Current: $264.59
Upside: n/a